热门资讯> 正文

在Roth购买了Brinsuri和Arikayce销售的新产品

2026-01-23 23:29

Insmed Incorporated(INSM) 0

Roth has initiated Insmed (INSM) at buy saying it sees above consensus sales of Brinsupri (brensocatib) and Arikayce (amikacin liposome inhalation suspension).
The firm set a $212 price target (~32% upside based on Jan. 22 close).
Analyst Adam Walsh sees Brinsupri peak sales of $8.1B and for Arikayce, $1.3B.
Walsh also highlighted the potential of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension given positive mid-stage trial results released in June 2025. He sees $5B probability of success-adjusted peak sales.

More on Insmed

Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Insmed Impresses With Pulmonary Portfolio, But Still Lacks Remedy To Turn A Profit
Insmed gains as preliminary 2025 revenue beats consensus
Insmed drops as it abandons brensocatib in rhinosinusitis

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。